Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways (VISUOPEV)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Visual morbidity (visual acuity and/or visual field deficit) must be taken into account during neurosurgical procedures for lesions near the optical pathways. Part of this morbidity is due to surgical manipulation. There is no validated tool for intraoperative visual monitoring and few publications have studied this issue.
In a preliminary work based on analysis of these publications, we defined technical, anaesthetic and analytical parameters in order to optimise intraoperative visual evoked potentials monitoring. These parameters are special devices used for transpalpebral stimulation, complete intravenous anaesthesia without halogen or nitrous oxide, and pertinent analysis criteria of visual evoked potential (VEP). We suppose that these improvements will increase reliability of intraoperative VEP.
| Condition | Intervention |
|---|---|
|
Surgery Optic Nerve and Pathway Injury |
Device: Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera® |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways |
- Evolution of visual function six months after surgery. [ Time Frame: Month 6 after surgery ] [ Designated as safety issue: No ]Visual function : visual field and visual acuity six months after surgery.
- Score of the visual field. [ Time Frame: Month 6 after surgery ] [ Designated as safety issue: No ]
- Score of visual acuity [ Time Frame: Month 6 after surgery ] [ Designated as safety issue: No ]
- Average diameter of the optic nerve fibers measured with Optical coherence tomography [ Time Frame: Month 6 after surgery ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | January 2014 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Patients |
Device: Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®
Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery. Flash and steady state visual evoked potential are measured during the surgical procedure at different times. |
Detailed Description:
This genuine optimised monitoring in France, set up in association with Metrovision company, should help increasing intraoperative VEP reliability as a monitoring tool for visual pathways function.
In this study, we assess the predictive value of relevant intraoperative variations of VEP (more than 50% variation of latency and amplitude) on the visual prognosis at six months after surgery The visual assessment consisting of a visual field, a visual acuity, and the performance of pattern transient VEP, will be performed by an ophthalmologist before surgery, and at three and six months after surgery. An electroencephalogram with photostimulatory lighting will be used in pre-operative and will validate the absence of photo-induced epilepsy risk.
During the intervention, VEPs associated to an electroretinogram will be performed by a neurosurgeon trained to the use of these tools by Metrovision company:
- Under general anaesthesia, but before any surgery.
- During the surgery, at predetermined surgical times (while performing the craniotomy or the sphenoid opening, at various times during the perioptic lesion dissection, after the lesion resection, when closing).
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with lesion compressing or near the optical pathways
Exclusion Criteria:
- Patients with photic epilepsy
Contacts and Locations| Contact: Daniel LAGUERRE, Dr | daniel.laguerre@chu-bordeaux.fr |
| France | |
| CHU Bordeaux - hôpital Pellegrin | Recruiting |
| Bordeaux, France, 33000 | |
| Contact: Daniel LAGUERRE, Dr daniel.laguerre@chu-bordeaux.fr | |
| Contact: Marie LEGALL marie.le-gall@chu-bordeaux.fr | |
| Principal Investigator: Daniel LAGUERRE, Dr | |
| Principal Investigator: | Daniel LAGUERRE, Dr | University Hospital, Bordeaux, France |
| Study Chair: | Paul PEREZ, Dr | University Hospital, Bordeaux, France |
More Information
No publications provided
| Responsible Party: | University Hospital, Bordeaux |
| ClinicalTrials.gov Identifier: | NCT01517789 History of Changes |
| Other Study ID Numbers: | CHUBX 2011/09 |
| Study First Received: | January 20, 2012 |
| Last Updated: | May 7, 2013 |
| Health Authority: | France: Ministry of Health |
Keywords provided by University Hospital, Bordeaux:
|
Surgery Optic Nerve and Pathway Injury visual event-related potential |
ClinicalTrials.gov processed this record on May 21, 2013